ClinicalTrials.gg

Program

niraparib

Also written as “Niraparib”, “MK-4827” and “ZL-2306(nirapairb)”.

Its studies are mostly in Ovarian Neoplasms · Neoplasms · Prostatic Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by 6 companies.

Furthest: phase 4, since Mar 19, 202539 company-led studies, 9 open or runningNext primary completion: Nov 26, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline236 open or runningphase 4since Mar 19, 2025Sep 5, 2008Nov 26, 2026phase 3 · NCT03981796
Johnson & Johnson53 open or runningphase 3since Nov 19, 2018Aug 1, 2016none ahead
Zai Lab50 open or runningphase 3since Apr 23, 2018Apr 20, 2018none ahead
Takeda30 open or runningphase 2since Nov 29, 2018Apr 5, 2018none ahead
Merck20 open or runningphase 1since Oct 21, 2010Oct 21, 2010none ahead
Tempus AI10 open or runningphase 2since Dec 13, 2021Dec 13, 2021none ahead

Also a collaborator on its studies: myriad-genetics-inc, Sarah Cannon Research Institute, sarah-cannon and myriad-genetic-laboratories-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Sep 5, 2008.

  1. Sep 19, 20182 phase 3 studiesZai Lab · NCT03709316, NCT03705156
  2. Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
  3. Nov 29, 20182 phase 2 studies in Ovarian NeoplasmsTakeda · NCT03759600, NCT03759587
  4. May 31, 2019Phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796 · 785 enrolled · United States, Belarus, Belgium and more
  5. May 13, 2020Phase 2 study in Ovarian NeoplasmsZai Lab · NCT04392102 · 15 enrolled · China
  6. Jul 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT04475939 · 666 enrolled · United States, Argentina, Australia and more
  7. Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
  8. Sep 4, 2020Phase 1 study in NeoplasmsGlaxoSmithKline · NCT04544995 · 47 enrolled · United Kingdom
  9. Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
  10. Nov 20, 2020Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247 · 37 planned · United States, Austria, Canada and more
  11. Jun 1, 2021Phase 3 study in Breast NeoplasmsGlaxoSmithKline · NCT04915755 · 40 enrolled · United States, Argentina, Australia and more
  12. Dec 13, 2021Tempus AI's first study: phase 2 study in Breast NeoplasmsNew to Tempus AITempus AI · NCT05169437 · 22 enrolled · United States
  13. Mar 19, 2025Phase 4 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06887933 · 67 planned
  14. Apr 30, 2025Phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT06964165 · 36 enrolled · United States, Canada, Spain

Ahead

  1. Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
  2. Dec 28, 2026Primary completion: phase 2 study in Ovarian NeoplasmsGlaxoSmithKline · NCT04641247

TargetBeta

PARP1 →PARP2 →read by rule
“Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
olaparibruleAstraZenecaphase 478
saruparibruleAstraZenecaphase 314
senaparibruleimpact-therapeutics-incphase 212
nesuparibruleJeil Pharmaceuticalphase 24

Studies

All 39 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06964165Ovarian Neoplasms · United States, Canada, Spain2TerminatedGlaxoSmithKlineJun 28, 202436
NCT06887933Ovarian Neoplasms4Not yet recruitingGlaxoSmithKlineMar 20, 202667
NCT05169437Breast Neoplasms · United States2TerminatedTempus AIAug 6, 202422
NCT04915755Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineJun 28, 202440
NCT04641247Ovarian Neoplasms · United States, Austria, Canada and more2RecruitingGlaxoSmithKlineDec 28, 202637
NCT04577833Prostatic Neoplasms · United States, Belgium, France and more1Active, not recruitingJohnson & JohnsonOct 15, 2021136
NCT04544995Neoplasms · United Kingdom1TerminatedGlaxoSmithKlineApr 23, 202547
NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJan 7, 2025696
NCT04475939Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineFeb 26, 2025666
NCT04392102Ovarian Neoplasms · China2CompletedZai LabApr 8, 202115
NCT03981796Neoplasms · United States, Belarus, Belgium and more3Active, not recruitingGlaxoSmithKlineNov 26, 2026785
NCT03759600Ovarian Neoplasms · Japan2CompletedTakedaDec 28, 202220
NCT03759587Ovarian Neoplasms · Japan2CompletedTakedaMar 17, 201919
NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonOct 8, 2021765
NCT03709316Ovarian Neoplasms · China3UNKNOWNZai LabJan 29, 2022384
NCT03705156Platinum-sensitive Relapsed Ovarian Cancer · China3UNKNOWNZai LabFeb 1, 2020265
NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more3Active, not recruitingGlaxoSmithKlineOct 31, 20241,400
NCT03516084Small Cell Lung Carcinoma · China3TerminatedZai LabFeb 21, 2020185
NCT03551171Ovarian Neoplasms · China1CompletedZai LabMay 3, 201842
NCT03497429Advanced Solid Tumors · Japan1CompletedTakedaFeb 10, 20209
NCT03329001Neoplasms · United States1CompletedGlaxoSmithKlineDec 30, 2021236
NCT03329937Breast Neoplasms1CompletedGlaxoSmithKlineJan 2, 202021
NCT03326193Ovarian Neoplasms · United States2CompletedGlaxoSmithKlineDec 24, 2020105
NCT03359850Ovarian Neoplasms · United States1CompletedGlaxoSmithKlineSep 16, 201917
NCT03308942Neoplasms · United States2CompletedGlaxoSmithKlineMay 4, 202053
NCT02924766Prostatic Neoplasms · United States, Canada1CompletedJohnson & JohnsonJul 18, 201934
NCT02854436Prostatic Neoplasms · United States, Australia, Belgium and more2CompletedJohnson & JohnsonJan 26, 2021289
NCT02657889Neoplasms · United States2CompletedGlaxoSmithKlineMay 14, 2018122
NCT02655016Ovarian Neoplasms · United States, Belgium, Denmark and more3Active, not recruitingGlaxoSmithKlineMay 17, 2019733
NCT02476552Neoplasms · Netherlands1CompletedGlaxoSmithKlineDec 201512
NCT02354586Ovarian Neoplasms · United States, Canada2CompletedGlaxoSmithKlineFeb 28, 2018463
NCT01905592Breast Neoplasms · United States, Belgium, Canada and more3TerminatedGlaxoSmithKlineMay 23, 2018216
NCT01847274Ovarian Neoplasms · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineApr 22, 2016596
NCT01294735Glioblastoma1CompletedMerckApr 201219
NCT01244009Lymphoma2WithdrawnGlaxoSmithKlineAug 20130
NCT01227941Ovarian Neoplasms1TerminatedGlaxoSmithKlineSep 20116
NCT01226901Neoplasms1TerminatedMerckFeb 20113
NCT01110603Neoplasms1TerminatedGlaxoSmithKlineJul 201112
NCT00749502Leukemia, Lymphocytic, Chronic, B-Cell1CompletedGlaxoSmithKlineSep 2011113

How it is read

Names in the registry

  • “Niraparib”, 25 entries
  • “MK-4827”, 5 entries
  • “ZL-2306(nirapairb)”, 2 entries
  • “niraparib”, 2 entries
  • “MK-4827 + pegylated liposomal doxorubicin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.